theMednetRegister

General Internal Medicine

Pulmonology   

Questions discussed in this category

Is there a role for dual antibiotic treatment with ethambutol and macrolide only, as opposed to three-drug antibiotic therapy, in the treatment of treatment-naive pulmonary MAC without cavitary disease?
4 Answers available
Do you recommend treating Candida albicans on urine culture from an indwelling catheter in a patient with septic shock?
3 Answers available
How do you approach PJP prophylaxis in patients with rheumatic disease on corticosteroids?
Does the presence of ILD change your approach?
4 Answers available
What is your approach to treatment of airway involvement, such as recurrent bronchial stenosis, in relapsing polychondritis?
Are there specific immunosuppressive agents effective for this manifestation?
2 Answers available
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Do you use TNF-i or MMF?
2 Answers available
Is methacholine challenge on its way out?
1 Answer available
What is your approach to therapy in patients with progressive Scedosporium pulmonary infection who are not candidates for surgical debridement?
1 Answer available
Do you treat patients with culture positive mycobacterium abscessus if they are asymptomatic and do not have progression on imaging?
1 Answer available
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
1 Answer available
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
Joint symptoms are stable on Hydroxychloroquine. Is there benefit of adding methotrexate or Rituximab for lung disease? CT of chest with predominately...
1 Answer available
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
1 Answer available
Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?
CT changes are subsolid and ground glass nodules.
2 Answers available
What are some immunosuppression regimens to consider in a patient with refractory cardiac sarcoidosis?
2 Answers available
When do you consider Cheyne-Stokes respirations noted in download data from positive pressure machines to be normal vs abnormal requiring intervention?
2 Answers available
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
Is there any utility in ACE levels and/or IL-2 levels in the diagnostic work-up of cardiac sarcoidosis? 
1 Answer available
Do you treat non-albicans strains of Candida on sputum culture or BAL in patients who are immunosuppressed?
2 Answers available
How do you approach the management of patients with mildly elevated mPAP (21-24 mmHg) and PVR (2-3 WU) who may be at risk of progression, given the recent changes in the hemodynamic definition of pulmonary hypertension?
Definition, classification and diagnosis of pulmonary hypertension (Kovacs et al., PMID 39209475).
2 Answers available
What features on PFT or flow-volume loops do you look at to suspect small airway dysfunction?
Often distal flattening of expiratory limb or decreased Fev25-50/FVC is referred for small airway dysfunction but it is advised against using it give ...
1 Answer available
Is there any role for prophylactic bronchial artery embolization in immunocompromised patients with invasive pulmonary aspergillosis?
1 Answer available
What is your approach to treatment in a patient with radiographic UIP but pathologic evidence of both fibrotic NSIP and UIP?
Do you start anti-inflammatory agents, anti-fibrotic agents, or both?
1 Answer available
Would you consider using DOACs as a bridge to warfarin instead of heparin or LMWH?
For example, would you consider this method in an ESRD/HD patient with antiphospholipid syndrome who had a major bleed requiring reversal of warfarin ...
4 Answers available
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
3 Answers available
How does your approach to subsegmental PE differ from segmental PE both diagnostically and therapeutically?
3 Answers available
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
2 Answers available
How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspired by the...
5 Answers available
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
A patient on meloxicam for LBP developed high, persistent fevers and no other symptoms. An IGRA, among many tests, was sent. The IGRA’s mitogen ...
2 Answers available
Do you obtain an MSLT or start empiric therapy with modafinil in patients with residual excessive daytime sleepiness despite optimal adherence to PAP therapy?
In patients with an average of less than 5 respiratory events per hour, adequate sleep duration and hygiene were confirmed on the sleep log, absent ca...
5 Answers available
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
2 Answers available
Is there any utility to trending Histoplasma serology titers to guide duration of therapy or treatment response for pulmonary histoplasmosis with negative urine antigen?
2 Answers available
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
Do you perform it on every suspected case, or are there specific indications you look for before proceeding with BAL?
2 Answers available
What further evaluation do you pursue for patients who present with vague symptoms such as subjective fevers or intermittent night sweats, who have no pulmonary symptoms but have a positive IGRA?
1 Answer available
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
1 Answer available
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspi...
1 Answer available
What is the duration of steroids that you prescribe for organizing pneumonia?
1 Answer available
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
A patient on meloxicam for LBP developed high, persistent fevers and no other symptoms. An IGRA, among many tests, was sent. The IGRA’s mitogen ...
2 Answers available
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
Pre-treatment troponin was mildly elevated, while ILR2 receptor, ACE, CRP, ESR were normal. 
1 Answer available
Do you favor timely bronchoscopy for diagnostics over close surveillance in mildly symptomatic patients with CT findings suspicious for NTM infection who are not able to expectorate?
4 Answers available
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
1 Answer available
What is your diagnostic approach to patients referred for central sleep apnea on PSG but normal overnight EEG and MRI?
1 Answer available
Have you adopted the use of low dose morphine for treatment of cough in patients with IPF?
If so, what dose and formulation of morphine do you prefer?The PACIFY COUGH trial utilized controlled-release morphine 5 mg BID, however the lowest do...
1 Answer available
Do you administer immunosuppression to patients with idiopathic NSIP who have normal lung function and mild to moderate respiratory symptoms?
1 Answer available
How do you approach the bronchoscopic evaluation of a cavitary lesion of the lung?
Do you routinely perform transbronchial biopsies in addition to BAL in all cases?
1 Answer available
What postural change in FVC is suggestive of respiratory muscle weakness?
2 Answers available
How do you manage patients with central sleep apnea due to heart failure with reduced ejection fraction?
Are there specific scenarios in which you employ BPAP with a back up rate?
1 Answer available
How do you read a PFT with restrictive type spirometry but normal lung volumes?
What clinical significance does this have and how do you follow these patients?
2 Answers available
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
1 Answer available
Would you treat a sputum culture positive for Aspergillus niger despite an atypical CT chest and a negative serum galactomannan in an immunosuppressed patient who is too high risk for bronchoscopy?
0 Answers available
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
Is this managed as CTD-ILD with immunosuppressive +/- anti-fibrotic agents?
1 Answer available
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
1 Answer available
How do you approach a patient on anti-TNF with positive Quantiferon (previously negative) with negative chest x-ray and no symptoms?
7 Answers available
What criteria do you use to determine when to start a steroid-sparing agent for hypersensitivity pneumonitis?
1 Answer available
Do you start immunosuppression for enlarging pulmonary nodules without symptoms, impaired pulmonary function, or extra-pulmonary disease in a patient with sarcoidosis?
1 Answer available
How do you workup patients with neuropathy suspected to be secondary to sarcoid?
Is a biopsy or EMG helpful in confirming the etiology? What is the best treatment for sarcoid neuropathy?
1 Answer available
What would be your recommendation for treatment of worsening lung disease in a patient with long-standing scleroderma after long-term mycophenolate therapy which is no longer an option due to side effect/intolerance?
3 Answers available
How do you determine the severity of restrictive lung disease?
1 Answer available
Do you hold anticoagulation prior to performing bronchoalveolar lavage?
1 Answer available
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
3 Answers available
How would you manage a patient with morbid obesity who presents with new symptomatic pulmonary embolism a few days after he was started on DOAC for DVT?
What is your preferred anticoagulation in patients with BMI >50?
5 Answers available
How would you approach the workup and management of isolated inflammatory subglottic stenosis in a young previously healthy patient that is steroid responsive with a completely negative serologic autoimmune workup?
Would you push for biopsy before deciding on treatment?
1 Answer available
How do you approach management of new onset ILD in a patient with RA who is otherwise well controlled on methotrexate or leflunomide?
1 Answer available
How would you manage cardiac sarcoid with intolerance/contraindications to methotrexate, azathioprine, and mycophenolate/mycophenolic acid and that has proven refractory to adalimumab and infliximab as determined by PET?
2 Answers available
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
4 Answers available
How do you approach the treatment of indeterminate UIP on HRCT with grossly positive MPO antibody and no other features consistent with AAV?
1 Answer available
Can transudative pleural effusions lead to trapped lung?
In trapped lung, a fibrous peel over the visceral pleura restricts pleural expansion. Could transudative pleural effusions lead to this condition?
1 Answer available
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
1 Answer available
Have you used Karius to aid in the diagnosis of a non-resolving pneumonia, with negative bronchoscopy, biopsy, and other infectious work up in an immunocompetent patient?
1 Answer available
Do you always comment on VA and KCO when reading PFT's when gas transfer is ordered?
1 Answer available
Do you favor the use of maximal inspiratory/expiratory pressure measurement or supine spirometry in the evaluation of a patient with suspected respiratory muscle weakness?
1 Answer available
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
Patient is with past history of glomerulonephritis in remission after rituximab for the past 2 years. +MPO/P-ANCA
1 Answer available
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?
1 Answer available
How do you prescribe a steroid taper for radiation and checkpoint inhibitor related pneumonitis?
I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...
2 Answers available
What serologic biomarkers do you send to assess for sarcoidosis at baseline and/or during flares, in patients where it may correlate with disease activity?
Specifically, do you check for any of these: ACE, Vitamin D 1,25, serum lysozyme, soluble IL2 or Adenosine deaminase levels?
1 Answer available
How do you approach management of adult patients with CVID and sarcoid-like syndrome?
1 Answer available
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
1 Answer available
Would you stop azathioprine in a patient with ANCA vasculitis who has been in long term remission on azathioprine, but has a new diagnosis of lung cancer requiring initiation of immunotherapy?
2 Answers available
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
2 Answers available
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
2 Answers available
For patients with suspected complement-mediated TMA, are there specific clinical or laboratory parameters that can help guide the decision for starting empirical treatment (e.g., eculizumab) while awaiting the results of complement testing?
1 Answer available
How do you manage diarrhea in a patient with CTD-ILD on MMF who was recently started on full dose nintedanib?
5 Answers available
Is there a role for repeat surveillance blood cultures in patients with prosthetic valve endocarditis without associated cardiac abscess after a 6 week course of antibiotic treatment without surgical intervention?
1 Answer available
Do you diagnose obstruction by the criteria of FEV1/FVC < 70% or < LLN?
5 Answers available
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
1 Answer available
In which patients do you prefer daily standard three-drug therapy for non-cavitary pulmonary MAC as opposed to three times a week dosing?
2 Answers available
Would you start any treatment for radiation pneumonitis if there is a large area of consolidation in the irradiated lung field but the patient is asymptomatic?
Would you consider pentoxifylline and vitamin E to mitigate fibrosis?
2 Answers available
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
1 Answer available
How do you determine if pulmonary hypertension is disproportionate to the severity of lung disease?
2 Answers available
What else do you consider in the differential diagnosis for pulmonary-renal syndromes if there is low clinical and serologic evidence of AAV, Goodpasture's or other rheumatologic disease (SLE, RA, APS, Scleroderma)?
2 Answers available
How do you risk stratify patients with different WHO groups of pulmonary hypertension prior to non-cardiac surgeries?
And who would you not recommend to undergo surgeries?
1 Answer available
How would you manage asymptomatic osseous sarcoidosis of the lumbar spine without any other systemic involvement?
Would you use with DMARDs/biologics or monitor?
1 Answer available
Do you use FVIII levels to differentiate between DIC and coagulopathy of liver disease?
Common thought is that FVIII may be used for differentiating coagulopathy in liver disease (normal to increased, from reduced clearance of VWF/FVIII) ...
4 Answers available
Do you consider immunosuppressive agents in progressive interstitial pneumonias or pneumonitis without a clear driving etiology?
1 Answer available
Do you consider pulmonary hypertension related to sarcoidosis to be an indication to start steroids?
Do you use biomarkers or PET scanning to stratify patients who may benefit most from therapy?
1 Answer available
How would you approach medication de-escalation in a patient with a history of rapidly progressive CTD-ILD who responded to and is currently on mycophenolate 3 grams daily and IVIG 2mg/kg monthly infusions and has been stable for two years?
2 Answers available
How do you approach management of a patient with Sjogren's disease and lung mass biopsy revealing amyloidosis?
1 Answer available
How do you approach management of a patient with idiopathic PAH and +ANA, but no other current symptoms/signs of active rheumatologic disease?
3 Answers available
Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?
This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).
2 Answers available
Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?
3 Answers available
What is your approach to monitoring patients with cardiac sarcoid while tapering immunosuppression?
Do you obtain serial cardiac PET scans?
1 Answer available
How do you manage immunosuppressive medications in patients who develop a pneumonia?
1 Answer available
What therapies do you routinely use to prevent mucus plug formation after endobronchial stent placement?
1 Answer available
What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?
2 Answers available
How long do you normally wait before considering any bronchoscopic procedure (EBUS-TBNA, Transbronchial biopsy) after an episode of acute PE in a patient needing these procedures?
Normally, waiting 6-12 weeks of therapeutic anticoagulation after an acute PE is suggested for any bronchoscopic procedure, however there is always a ...
1 Answer available
What are your top takeaways from CHEST 2023?
2 Answers available
What is your approach to a patient who has a cardiac PET scan suggestive of sarcoid but no other supporting evidence of a diagnosis of sarcoid?
Do you typically push for myocardial biopsy in this case? 
1 Answer available
Are the results of the BOREAS trial generalizable to non-white populations?
The cohort in the study was predominantly white. Do these results highlight significant disparities in COPD care?
2 Answers available
What is your approach in differentiating IPAF (interstitial pneumonia with autoimmune features) versus "CTD ILD" in patients with serologic abnormalities but do not fulfill criteria for autoimmune disease?
1 Answer available
Have you seen rheumatoid nodules or RA-ILD in patients with seronegative RA?
While classically described as seen in seropositive patients, have they been reported in seronegative RA?
2 Answers available
How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?
2 Answers available
What is your approach to initial work up for a young patient with bronchiectasis?
2 Answers available
What is your initial treatment of choice in patients with RA and associated interstitial lung disease?
1 Answer available
How do you manage GI side effects related to CFTR modulator therapy?
2 Answers available
Is there a role for biologics to help patients with ABPA who are steroid responsive and have removed their allergen insult, but continue to have an elevated serum IgE and incomplete resolution of symptoms return to their baseline functional status?
1 Answer available
Is there a role for the use of biologics as steroid sparing agents in treating patients with ABPA who are intolerant to prednisone?
1 Answer available
What is your approach to using nintedanib in patients on baseline immunosuppression?
Patients on baseline mycophenolate and azathioprine were excluded from the INBUILD trial however many patients with CTD-ILD will be on some form of im...
5 Answers available
Would you consider the use of dual antifibrotic therapy (nintedanib and pirfenidone together) for progressive fibrosing ILD?
4 Answers available
Does your approach to treating latent tuberculosis differ in a patient on anti-fibrotic therapy?
1 Answer available
Do you routinely use hypertonic saline for pulmonary toileting in patients with non-CF bronchiectasis?
1 Answer available
When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?
Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?
6 Answers available
What is your approach to management of elderly patients with cardiopulmonary comorbidities and severe pulmonary hypertension?
1 Answer available
Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?
3 Answers available
How do you define an adequate EBUS when staging NSCLC?
Is there a minimum standard for which stations to sample? Does lymph node size affect your recommendations?
3 Answers available
Are you using NAC in lieu of hypertonic saline amidst the current shortage of hypertonic saline in patients with either CF or non-CF bronchiectasis?
1 Answer available
What is your approach to the monitoring and management of a never-smoker with respiratory symptoms and a nonspecific ventilatory pattern on pulmonary function testing?
1 Answer available
What dose and duration of steroid therapy do you use in steroid responsive ILD?
1 Answer available
What is the optimal frequency and duration of post-operative radiological surveillance following resection of a solitary fibrous tumor?
1 Answer available
Do you offer immunosuppression to patients with CTD-ILD with concomitant well controlled HIV?
2 Answers available
Are you using the microbial cell-free DNA “Karius” test to aid in the diagnosis of an atypical pulmonary infection such as PJP or NTM?
2 Answers available
How do you manage recurrent inflammatory pleural effusions in lupus pleuritis?
1 Answer available
What is your approach to therapy for pulmonary sarcoidosis resistant to methotrexate?
1 Answer available
How would you treat a patient with combined pre- and post-capillary pulmonary hypertension after successfully optimizing post-capillary pressures through a valvular intervention?
2 Answers available
Do you routinely isolate and test for TB in a patient incidentally found to have a miliary pattern of nodules on chest CT?
2 Answers available
What is your approach to pulmonary vasodilator therapy in patients with COPD and Severe Group 3 Pulmonary Hypertension?
1 Answer available
Does your approach to the management of a patient with an acute exacerbation of CPFE where the ILD is attributed to IPF differ from the management of a patient with an exacerbation of IPF alone?
1 Answer available
What is your approach to the management of a patient with PAH who is resistant to contraception and planning a pregnancy?
1 Answer available
Do you prescribe antifibrotics to patients with combined pulmonary fibrosis and emphysema (CPFE)?
1 Answer available
When can abdominal surgery be safely performed for presumptive ovarian cancer in a patient with recent pulmonary emboli?
(Normal oxygenation and echo)
1 Answer available
Do you treat Candida spp isolated from a bronchoalveolar lavage?
1 Answer available
Is there a role for biologic therapies in asthma-COPD overlap syndrome with evidence of type 2 inflammation?
2 Answers available
What is your approach to the work up and management of interstitial lung abnormalities?
1 Answer available
Do you routinely continue airway clearance therapies in the setting of mild to moderate hemoptysis in a patient with CF?
2 Answers available
Would you consider prophylactic antifungal treatment prior to immunosuppressive therapies in a patient with previously treated pulmonary coccidiomycosis and residual parenchymal changes?
1 Answer available
Do you do recommend further mediastinal staging for patients with SCLC or inoperable NSCLC with N1 disease on PET?
If a patient clearly has N1 disease with high SUV on PET, do you routinely recommend EBUS or mediastinoscopy to evaluate for N2 disease?
1 Answer available
What patient characteristics would lead you to opt for triple therapy versus double therapy in newly diagnosed PAH?
1 Answer available
What steroid regimen do you employ in the treatment of patients with post COVID-19 pulmonary fibrosis?
2 Answers available
Do you favor the use of Fick or thermodiluation to measure cardiac output in patients with interstitial lung disease with suspected pulmonary hypertension?
Occasionally, supplemental oxygen may alter Fick measurements giving falsely high CO and falsely low PVR, therefore is Thermodilution method preferred...
2 Answers available
Which images do you routinely request when ordering a HRCT chest?
1 Answer available
What workup do you do for patients who have PL-7 elevation when screening for myopathy?
2 Answers available
What criteria do you use to consider pleurodesis vs indwelling tunneled catheters in patients with malignant pleural effusion?
1 Answer available
How do you counsel patients regarding prognosis following a diagnosis of IPF?
1 Answer available
How do you approach a thoracic lymph node that is highly suspicious on CT and PET but negative on EBUS in patients with NSCLC?
3 Answers available
Do you adjust immunosuppression in lung transplant recipients diagnosed with COVID-19?
2 Answers available
Is there a role for the use of inhaled corticosteroids in patients with pulmonary sarcoidosis who have stage II or III disease with abnormal lung function but only mild respiratory symptoms?
1 Answer available
How do you clinically distinguish between group I and group III PH in patients with CTD-ILD?
1 Answer available
Do you utilize soluble IL-2 receptor or ACE levels as serum biomarkers to monitor disease activity in pulmonary sarcoidosis?
1 Answer available
Based on findings of the INCREASE trial, are you routinely prescribing inhaled treprostinil to patients with group 3 pulmonary hypertension secondary to interstitial lung disease?
1 Answer available
How do you treat patients with sarcoid who have persistent symptoms after an initial 6 week course of corticosteroids?
3 Answers available
Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD who have not yet demonstrated evidence of a progressive phenotype?
1 Answer available
When would you consider biopsy for an incidentally noted, PET negative, solid, solitary pulmonary nodule that is >8mm in size?
1 Answer available
Is there a role for antifibrotic therapy in post COVID-19 pulmonary fibrosis?
1 Answer available
Do you consider EBUS TBNA in the diagnostic evaluation of patients with mediastinal lymphadenopathy with concern for lymphoma?
1 Answer available
What are best practices for engaging with multidisciplinary colleagues to ensure patients with earlier stage NSCLC are being appropriately considered for novel adjuvant therapies?
How are your teams effectively evaluating and counseling patients to ensure they are prepared for potential extended adjuvant treatment approaches? Is...
4 Answers available
What is your approach to treatment for a patient with progressive ILD (UIP pattern) with high titer RF but no articular symptoms?
1 Answer available
What are your recommendations regarding methotrexate usage in patients with persistent chest CT changes post COVID pneumonia?
Would you have a different opinion based on whether it is a new therapy or an existing and previously well-tolerated therapy for the patient?
2 Answers available
How do you evaluate a suspicious, but negative pleural effusion when working up NSCLC and SCLC?
Are two negative pleurocentesis' adequate to conclude that the patient does not have metastatic disease? Do you routinely recommend VATS and pleural b...
1 Answer available
What criteria do you use on echocardiogram and PFT to determine who needs further evaluation for CTD-associated pulmonary hypertension?
1 Answer available
What indicators do you use to identify patients with CTD-ILD who do not have potential to improve from continued immunosuppressive therapy?
Do you use imaging (fibrosis vs. pneumonitis), PFTs, duration of prior immunosuppressive therapy?
1 Answer available
What immunosuppressive agents aside from steroids would you use to treat bronchiolitis obliterans in a patient with long-standing seropositive RA?
1 Answer available
Would you use inhaled steroids with or without oral steroids for the treatment of radiation pneumonitis?
Would inhaled steroids help reduce the PO dose and/or significantly accelerate tapering?  If s, for what pneumonitis grade? What specific steroid...
1 Answer available
Are there any concerns about using nintedanib in a patient with progressive fibrosing ILD on background mycophenolate?
1 Answer available
How do you treat CTD-associated organizing pneumonia?
How is your approach to treatment different than other ILD patterns such as NSIP? Does treatment response vary based on underlying CTD?
2 Answers available
How do you treat RA in patients with pulmonary mycobacterium avium complex (MAC) infections?
1 Answer available
Can liquid biopsy be substituted for tissue biopsy in a lung mass that is radiologically suspicious for primary lung cancer when CT-guided biopsy cannot be done?
For example, a patient with a large (>3cm), spiculated, FDG-avid lung lesion, who has poor lung function and is refusing a CT-guided biopsy?
2 Answers available
What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide? 
1 Answer available
How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?
1 Answer available
Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?
2 Answers available
When a patient presents with 2 lung lesions, do you routinely recommend a biopsy of both lung lesions?
Would your practice change if the patient had N2 disease?
1 Answer available
When do you use tacrolimus in patients with myositis-related interstitial lung disease?
1 Answer available
When do you stop immunosuppressants in patients with GPA?
1 Answer available
What is your next step in patients with polymyositis without interstitial lung disease who are refractory to methotrexate?
1 Answer available
How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available
Should patients with idiopathic pulmonary fibrosis be placed on nintedanib or pirfenidone before starting radiotherapy for lung cancer?
1 Answer available
How do you approach the workup of subcentimeter contralateral nodules in cases of locally advanced NSCLC?
When there is biopsy proven mediastinal disease, do you offer definitive chemoradiation and monitor, or do you try to prove the presence/absence ...
1 Answer available
When is it considered inappropriate to omit pathological mediastinal lymph node staging for non-small cell lung cancer?
The NCCN guidelines call for pathological mediastinal lymph node staging for all NSCLC except in solid tumors <1cm and non-solid lesions < ...
3 Answers available
When do you start steroids for radiation pneumonitis?
Following lung RT, I have rarely seen patients present with pneumonia-like symptoms of radiation pneumonitis. I'm more likely to see a patient with wo...
3 Answers available
If a PET/CT scan is positive for mediastinal lymph node involvement, is a mediastinoscopy or EBUS still required for NSCLC staging?
In practice, do you send patients with N2/3 disease for mediastinal staging if not offered upfront?
1 Answer available


Papers discussed in this category

J Thorac Cardiovasc Surg, 2011 Mar
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial.
Semin Radiat Oncol, 2015 Oct
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.
J. Clin. Oncol., 2008-07-20
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Chest, 2007 Sep
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).
Int. J. Radiat. Oncol. Biol. Phys., 2010-06-01
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study.
Thorac Cancer, 2017 Apr 24
Relationship between endobronchial ultrasound-guided (EBUS)-transbronchial needle aspiration utility and computed tomography staging, node size at EBUS, and positron emission tomography scan node standard uptake values: A retrospective analysis.
Autoimmunity reviews, 2021 Apr 19
Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.
Arthritis & rheumatology (Hoboken, N.J.), 2024 Jul 08
2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Rheumatology international, 2023 Apr 18
Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis.
Autoimmunity reviews, 2024 Sep 11
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis.
Ann. Rheum. Dis., 2018 May 03
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Ann. Rheum. Dis., 2018 Apr 25
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
The Lancet. Respiratory medicine, 2016-09
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
The New England journal of medicine, 2006-06-22
Cyclophosphamide versus placebo in scleroderma lung disease.
Nature reviews. Rheumatology, 2018-05
Treatment in myositis.
Lancet Respir Med, 2020 Aug 28
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Trials, 2017 Jun 15
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
N Engl J Med, 2019 Sep 29
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
N. Engl. J. Med., 2019 May 20
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
N Engl J Med, 2012 May 20
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Annals of the rheumatic diseases, 2022 Nov 03
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.
Frontiers in immunology, 2021 Apr 12
Using Routine Laboratory Markers and Immunological Indicators for Predicting Pneumonia in Immunocompromised Patients.
Arthritis Rheum,
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Eur Heart J, 2015 Aug 29
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
Eur Respir J, 2019 Jan 24
Diagnosis of pulmonary hypertension.
BMJ Open, 2019 May 05
Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.
Rheumatol Int, 2021 Jan 29
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review.
Eur Respir Rev, 2021 Dec 15
Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection.
Ann Am Thorac Soc,
Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment.
American journal of respiratory and critical care medicine, 2010-08-01
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2002-10
Use of fluticasone in acute symptomatic pulmonary sarcoidosis.
Eur Respir J,
Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study.
Eur Respir J,
Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis.
J Intern Med,
No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study.
Eur Respir J, 2021 Dec 16
ERS clinical practice guidelines on treatment of sarcoidosis.
N Engl J Med, 2021 Jan 13
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.
Lancet Respir Med, 2021 Jun 29
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
N Engl J Med, 2022 Sep 04
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.
The European respiratory journal, 2015-10
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000-04
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.
Chest, 2018 Jan 11
A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma.
J Allergy Clin Immunol Pract, 2021 Mar 06
Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization.
Chest, 2020 Aug 31
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
J Allergy Clin Immunol Pract, 2020 Jun 16
Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization.
Cureus, 2020 Aug 12
Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases.
J Allergy Clin Immunol Pract, 2015 Jan 29
Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.
The European respiratory journal, 2019-01
Risk stratification and medical therapy of pulmonary arterial hypertension.
Eur Respir J, 2019 Jan 24
Pulmonary hypertension in chronic lung disease and hypoxia.
Chest, 2011-06
Rapid pleurodesis for malignant pleural effusions: a pilot study.
JAMA,
Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.
JAMA,
Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial.
American journal of respiratory and critical care medicine, 2011-02-15
Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Chest, 2011-07
Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.
The Lancet. Respiratory medicine, 2017-12
Palliative care in interstitial lung disease: living well.
J Heart Lung Transplant, 2021 Nov
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
ERJ Open Res, 2019 Jul 08
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.
BMC Pulm Med, 2018 Jan 17
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey.
American journal of respiratory and critical care medicine, 2013-04-01
Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.
Am J Respir Crit Care Med,
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
The European respiratory journal, 2018-08
Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
J Am Coll Cardiol,
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Rheumatology (Oxford, England), 2017-06-01
A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.
Autoimmun Rev, 2012 Jul 05
Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
Arthritis & rheumatology (Hoboken, N.J.), 2017-03
Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Lancet Respir Med, 2021 Jan
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Am J Respir Crit Care Med,
Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension.
Lancet Respir Med,
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society.
Eur Respir Rev, 2022 Apr 13
Incidental discovery of interstitial lung disease: diagnostic approach, surveillance and perspectives.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2022 Jun 11
Identification and Prognosis of Patients With Interstitial Pneumonia With Autoimmune Features.
European respiratory review : an official journal of the European Respiratory Society, 2021 Dec 22
Interstitial pneumonia with autoimmune features: challenges and controversies.
Eur Respir J, 2019 Apr 18
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.
Am J Obstet Gynecol MFM, 2021 Mar 27
Pregnancy and pulmonary arterial hypertension: a case series and literature review.
Respirology, 2013 Nov 29
Rituximab in severe, treatment-refractory interstitial lung disease.
Respir Res, 2022 Jun 21
Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.
Circulation, 2013-07-30
Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.
The European respiratory journal, 2018-02
Macitentan in pulmonary hypertension due to left ventricular dysfunction.
Circulation, 2011 Jun 27
Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
Int J Cardiol, 2019 Jan 04
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Cochrane Database Syst Rev, 2019 Jan 31
Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Chest, 2014 Nov
Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
Circulation, 2021 Feb 08
Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
N Engl J Med, 2021 Aug 27
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
ERJ Open Res, 2022 Feb 21
Treatment of pulmonary hypertension associated with COPD: a systematic review.
European journal of internal medicine, 2023 Sep 04
Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis.
J Infect Dis, 2020 Jun 11
Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls.
Clin Chest Med, 2013 Apr 08
Interstitial lung disease in HIV.
Hepatology, 1996 Jun
Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure.
Hepatology, 1986 Jul-Aug
Multivariate analysis of prognostic factors in fulminant hepatitis B.
Gut, 1992 Jan
Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators.
Chest, 2016-03
Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report.
Chest, 2008 Feb 08
Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer.
JAMA, 2010 Nov 24
Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial.
Eur Respir J, 2017 Sep 09
European Respiratory Society guidelines for the management of adult bronchiectasis.
Thorax, 2019 Jan
British Thoracic Society Guideline for bronchiectasis in adults.
Clin Med Insights Circ Respir Pulm Med, 2021 Mar 30
Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib.
Cureus, 2022 Sep 06
Mycophenolate Mofetil-Induced Cytomegalovirus Colitis in a Patient With Polymyositis.
Respir Res, 2023 Jan 9
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
J Thromb Haemost, 2021 Jul 14
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
Blood, 2020 Mar 19
How I treat obese patients with oral anticoagulants.
Ann Am Thorac Soc, 2017 May
Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy.
Journal of clinical medicine, 2020 Dec 23
Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.
Chest, 2023 Feb 17
Patient-Reported Symptom and Health-Related Quality-of-Life Validation and Responsiveness During the First 6 Months of Treatment for Mycobacterium avium Complex Pulmonary Disease.
The New England journal of medicine, 2014 Oct 01
Goal-directed resuscitation for patients with early septic shock.
Circulation, 2015 Sep 15
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.
The Annals of thoracic surgery, 2017 Feb 04
Surgical Versus Medical Therapy for Prosthetic Valve Endocarditis: A Meta-Analysis of 32 Studies.
European heart journal, 2023 Oct 14
2023 ESC Guidelines for the management of endocarditis.
Arthritis & rheumatology (Hoboken, N.J.), 2015-05
Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
International journal of rheumatic diseases, 2014-02
Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18
Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
Clinical nuclear medicine, 2016-05
FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.
J Investig Med High Impact Case Rep, 2021 Jan-Dec
Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate.
Clinical therapeutics, 2018 Feb
Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
Heart rhythm, 2014-07
HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis.
Circulation journal : official journal of the Japanese Circulation Society, 2019 Oct 09
JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis　- Digest Version.
Rheumatology (Oxford, England), 2011 Dec 30
Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission.
Arrhythmia & electrophysiology review, 2020 Dec
Management of Cardiac Sarcoidosis in 2020.
Arthritis Rheumatol, 2021 Jul
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2021 Nov 12
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres.
Radiographics : a review publication of the Radiological Society of North America, Inc, 2013 Nov-Dec
CT findings of thoracic manifestations of primary Sjögren syndrome: radiologic-pathologic correlation.
British journal of haematology, 2024 Sep 02
Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline.
European respiratory review : an official journal of the European Respiratory Society, 2021 Nov 08
Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review.
Circulation, 2023 Mar 16
Evaluation and Management of Pulmonary Hypertension in Noncardiac Surgery: A Scientific Statement From the American Heart Association.
JAMA neurology, 2018-12-01
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group.
Journal of neuroimmunology, 2022 Apr 09
Peripheral neuropathy in sarcoidosis.
International journal of radiation oncology, biology, physics, 2023 Mar 07
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.
The European respiratory journal, 2023 Feb 09
Effect of adaptive servo-ventilation for central sleep apnoea in systolic heart failure on muscle sympathetic nerve activity: a SERVE-HF randomised ancillary study.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2017 Nov 15
Distinct Patterns of Hyperpnea During Cheyne-Stokes Respiration: Implication for Cardiac Function in Patients With Heart Failure.
Expert review of respiratory medicine, 2023 Jun 23
Diagnostic accuracy of interleukin-2 receptor in sarcoidosis: a systematic review and meta-analysis.
JAMA network open, 2023 Aug 01
Prevalence of and Eligibility for Surveillance Without Anticoagulation Among Adults With Lower-Risk Acute Subsegmental Pulmonary Embolism.
Blood, 2013 Jun 04
Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism.
Annals of internal medicine, 2021 Nov 23
Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study.
AJR Am J Roentgenol,
Overdiagnosis of Pulmonary Embolism by Pulmonary CT Angiography.
Current opinion in pulmonary medicine, 2013 Sep
Common variable immunodeficiency-associated granulomatous and interstitial lung disease.
Annals of the rheumatic diseases, 2024 Jan 11
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2012-08
Cyclophosphamide without corticosteroids for treatment of severe systemic necrotizing vasculitis.
Current medical research and opinion, 2016-12
Corticosteroids: the knee jerk response.
Lancet (London, England), 2011-05-21
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
The New England journal of medicine, 2018 Aug 26
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Respiratory research, 2021 Apr 26
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
The New England journal of medicine, 2014 May 18
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Respiratory investigation, 2020 Sep 03
Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
Advances in therapy, 2023 Mar 16
A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
American journal of respiratory and critical care medicine, 2011-10-01
Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study.
American journal of respiratory and critical care medicine, 2019 Jul 15
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis.
American journal of respiratory and critical care medicine, 2023 Jan 01
Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015-05
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
J Immunother Cancer, 2021 Jul
Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016 Jul 07
Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis.
Arthritis & rheumatology (Hoboken, N.J.), 2019 Oct 21
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
European journal of cancer (Oxford, England : 1990), 2023 Dec 28
Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
Arthritis and rheumatism, 2006 Mar
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
Sleep, 2007-06
Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning.
Current opinion in pulmonary medicine, 2023 Jun 30
Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment.
Rheumatology (Oxford, England), 2023 Feb 01
Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality.
International journal of cardiology. Heart & vasculature, 2021 Apr 29
Non-steroidal treatment of cardiac sarcoidosis: A systematic review.
The European respiratory journal, 2005-11
Interpretative strategies for lung function tests.
The European respiratory journal, 2022 Jul 13
ERS/ATS technical standard on interpretive strategies for routine lung function tests.
PloS one, 2024 Jun 13
Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis.
JAMA otolaryngology-- head & neck surgery, 2020 Jan 01
Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2024 Mar 14
Medical Maintenance Therapy Following Laser Excision in Patients With Granulomatosis With Polyangiitis (GPA)-Associated Subglottic Stenosis.
Neurology, 2001-07-24
Postural change of forced vital capacity predicts some respiratory symptoms in ALS.
The European respiratory journal, 2019-06
ERS statement on respiratory muscle testing at rest and during exercise.
Chest, 2017-03
Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis.
ERJ open research, 2017-07
Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis.
Chest, 2023 Dec 19
Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis.
The European respiratory journal, 2023 Nov 29
Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease.
The European respiratory journal, 2014 Aug 07
Sarcoidosis and subsequent cancer risk: a Danish nationwide cohort study.
Journal of clinical medicine, 2024 Jan 07
Infectious Complications of Pulmonary Sarcoidosis.
Rheumatology (Oxford),
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.
Rheumatology (Oxford, England), 2023 Dec 01
Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2004-03
Leflunomide for chronic sarcoidosis.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2000-03
Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.
Chest, 2003-07
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.
American journal of respiratory and critical care medicine, 2006-10-01
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
Diagnostics (Basel, Switzerland), 2024 Jan 23
A Retrospective Analysis of 2-Year Follow-Up of Patients with Incidental Findings of Sarcoidosis.
Chest, 1999 Aug
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group.
Respiration; international review of thoracic diseases, 2012 Dec 29
Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study.
The Lancet. Respiratory medicine, 2024 Jan 15
Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.
NEJM evidence, 2023 May 22
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis.
Chest, 2005-01
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
American journal of respiratory and critical care medicine, 2002 Jan 15
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.
Clinics in chest medicine, 2004 Dec
Cryptogenic organizing pneumonia.
N Engl J Med, 2020 Feb 13
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
N Engl J Med, 2021 Feb 18
Avacopan for the Treatment of ANCA-Associated Vasculitis.
The European respiratory journal, 2020 Aug 06
Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis.
American journal of respiratory and critical care medicine, 2020 Aug 01
Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.
American journal of respiratory and critical care medicine, 2019-11-01
Rare Protein-Altering Telomere-related Gene Variants in Patients with Chronic Hypersensitivity Pneumonitis.
The European respiratory journal, 2021 Mar 04
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis.
Rheumatology (Oxford, England), 2020 Dec 01
Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.
Journal of asthma and allergy, 2019
Two vs four puffs of albuterol: does dose change bronchodilator response?
Chest, 2020 Sep 01
Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
The European respiratory journal, 2009 Mar 26
Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review.
American journal of respiratory and critical care medicine, 2013-09-15
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
Journal of thoracic disease, 2024 Jan 11
Surgical lung biopsy for suspected interstitial lung disease with video-assisted thoracoscopic surgery is safe, providing exact histological and disease specific diagnosis for tailoring treatment.

Related Topics in General Internal Medicine

Copyright © 2025 theMednet
All Rights Reserved.